Raloxifene/SBE-β-CD Inclusion Complexes Formulated into Nanoparticles with Chitosan to Overcome the Absorption Barrier for Bioavailability Enhancement
Raloxifene (RXF) is a hormone-like medication used for treating postmenopausal osteoporosis and estrogen-dependent breast cancer, yet associated with bad low bioavailability due to poor solubility. This study was intended to develop cyclodextrin/chitosan nanoparticles (ccNPs) for oral delivery of RX...
Main Authors: | Zaihua Wang, Yan Li |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-06-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | http://www.mdpi.com/1999-4923/10/3/76 |
Similar Items
-
Bioadhesive polymer/lipid hybrid nanoparticles as oral delivery system of raloxifene with enhancive intestinal retention and bioavailability
by: Xinhui Du, et al.
Published: (2021-01-01) -
Formulation and Evaluation of a Self-Microemulsifying Drug Delivery System of Raloxifene with Improved Solubility and Oral Bioavailability
by: Muhammad Mohsin Ansari, et al.
Published: (2023-08-01) -
Oral Bioavailability Enhancement of Raloxifene with Nanostructured Lipid Carriers
by: Aditya Murthy, et al.
Published: (2020-05-01) -
A Non-Lipolysis Nanoemulsion Improved Oral Bioavailability by Reducing the First-Pass Metabolism of Raloxifene, and Related Absorption Mechanisms Being Studied
by: Ye JY, et al.
Published: (2020-08-01) -
LC-UV method to assay raloxifene hydrochloride in rat plasma and its application to a pharmacokinetic study
by: Márcia Camponogara Fontana, et al.